. Author manuscript; available in PMC: 2020 Jun 2.

Published in final edited form as: Surgery. 2018 May 25;164(3):424–431. doi: 10.1016/j.surg.2018.04.014

Table 3.

Adverse events at 90-days of consecutive patients treated prior to and after implementation of the risk-stratified pancreatectomy clinical pathways (N = 375).

	Historic (N=315)	RSPCP (N=60)	P-value
Any AE	239 (76%)	48 (80%)	.489
Severe AE (grade ≥ 3)	90 (29%)	19 (32%)	.628
DGE grade B/C	43 (14%)	2 (3%)	.024
POPF grade B/C	64 (20%)	14 (23%)	.598
PPH grade B/C	15 (5%)	2 (3%)	.626
Intra-abdominal abscess	27 (9%)	4 (7%)	.623
Wound infection	41 (13%)	11 (18%)	.275
Median stay, days (IQR)	10 (8-13)	6 (5-8)	<.001
Discharge to home	311 (99%)	60 (100%)	.380
90-day readmission	68 (22%)	14 (23%)	.764
90-day mortality	1 (0%)	0 (0%)	.662

AE = adverse event; DGE = delayed gastric emptying; POPF = postoperative pancreatic fistula; PPH = post-pancreatectomy hemorrhage